MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer

被引:51
|
作者
Goorts, Briete X. Z. [1 ,2 ,3 ]
Dreuning, Kelly M. A. [2 ]
Houwers, Janneke B. [3 ]
Kooreman, Loes F. S. [1 ,4 ]
Boerma, Evert-Jan G. [5 ]
Mann, Ritse M. [6 ]
Lobbes, Marc B. I. [1 ,3 ]
Smidt, Marjolein L. [1 ,2 ]
机构
[1] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands
[5] Zuyderland Med Ctr, Dept Surg, Sittard Geleen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands
来源
BREAST CANCER RESEARCH | 2018年 / 20卷
关键词
Breast Cancer; Neoadjuvant chemotherapy; Magnetic resonance imaging; RECOMMENDATIONS; THERAPY; UPDATE; TRIAL;
D O I
10.1186/s13058-018-0950-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability.& para;& para;Methods: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response); type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5 (progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation between MRI-based response patterns and pathological tumor reduction was studied with Pearson's correlation coefficient, and interobserver agreement was tested with Cohen's Kappa.& para;& para;Results: Patients (n = 76; mean age 53, range 29-72 years) with 80 tumors (4 bilateral) were included. There was significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2 patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and tumor reduction rates on pathology assessment (reader 1 r = - 0.17; p = 0.145 and reader 2 r = - 0.17; p = 0.146). In 41% of tumors with type 0 after NAC, pathology assessment showed pCR.& para;& para;Conclusion: MRI-based response patterns halfway through NAC can predict pathologic response more accurately than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR, while complete radiological response after NAC seems to be correct in only 41% of cases.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy
    Asaoka, Mariko
    Narui, Kazutaka
    Suganuma, Nobuyasu
    Chishima, Takashi
    Yamada, Akimitsu
    Sugae, Sadatoshi
    Kawai, Saori
    Uenaka, Natsuki
    Teraoka, Saeko
    Miyahara, Kana
    Kawate, Takahiko
    Sato, Eichi
    Nagao, Toshitaka
    Matsubara, Yuka
    Gandhi, Shipra
    Takabe, Kazuaki
    Ishikawa, Takashi
    EJSO, 2019, 45 (12): : 2289 - 2294
  • [32] Can peritumoral edema evaluated by Magnetic Resonance Imaging before neoadjuvant chemotherapy predict complete pathological response in breast cancer?
    Cakir Pekoz, Burcak
    Dilek, Okan
    Koseci, Tolga
    Tas, Zeynel Abidin
    Irkorucu, Oktay
    Gulek, Bozkurt
    SCOTTISH MEDICAL JOURNAL, 2023, 68 (03) : 121 - 128
  • [33] The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes
    Kuzmova, Miroslava
    Cullinane, Carolyn
    Rutherford, Claire
    Mccartan, Damian
    Rothwell, Jane
    Evoy, Denis
    Geraghty, James
    Prichard, Ruth S.
    SURGICAL ONCOLOGY-OXFORD, 2023, 51
  • [34] Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI
    Zhang, Man-Qi
    Liu, Xin-Pei
    Du, Yu
    Zha, Hai-Ling
    Zha, Xiao-Ming
    Wang, Jue
    Liu, Xiao-An
    Wang, Shou-Ju
    Zou, Qi-Gui
    Zhang, Jiu-Lou
    Li, Cui-Ying
    BRITISH JOURNAL OF RADIOLOGY, 2024, 97 (1153): : 228 - 236
  • [35] Changes in Automated Mammographic Breast Density Can Predict Pathological Response After Neoadjuvant Chemotherapy in Breast Cancer
    Ahn, Jee Hyun
    Go, Jieon
    Lee, Suk Jun
    Kim, Jee Ye
    Park, Hyung Seok
    Kim, Seung Il
    Park, Byeong-Woo
    Park, Vivian Youngjean
    Yoon, Jung Hyun
    Kim, Min Jung
    Park, Seho
    KOREAN JOURNAL OF RADIOLOGY, 2023, 24 (05) : 384 - 394
  • [36] Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response
    Chen, Christina A.
    Hayward, Jessica H.
    Woodard, Genevieve A.
    Ray, Kimberly M.
    Starr, Christopher J.
    Hylton, Nola M.
    Joe, Bonnie N.
    Lee, Amie Y.
    JOURNAL OF BREAST IMAGING, 2019, 1 (03) : 217 - 222
  • [37] Do decreased breast microcalcifications after neoadjuvant chemotherapy predict pathological complete response?
    Fushimi, Atsushi
    Kudo, Rei
    Takeyama, Hiroshi
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Can we identify "twin patients" to predict response to neoadjuvant chemotherapy in breast cancer?
    Orlhac, Fanny
    Cassou-Mounat, Thibaut
    Pierga, Jean-Yves
    Luporsi, Marie
    Nioche, Christophe
    Bouveyron, Charles
    Ayache, Nicholas
    Jehanno, Nina
    Livartowski, Alain
    Buvat, Irene
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [39] Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
    Heil, Joerg
    Schaefgen, Benedikt
    Sinn, Peter
    Richter, Hannah
    Harcos, Aba
    Gomez, Christina
    Stieber, Anne
    Hennigs, Andre
    Rauch, Geraldine
    Schuetz, Florian
    Sohn, Christof
    Schneeweiss, Andreas
    Golatta, Michael
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : 142 - 150
  • [40] Racial disparities in pathological complete response among breast cancer patients receiving neoadjuvant chemotherapy
    Zhao, Fangyuan
    Steiner, Meghan
    Ibraheem, Abiola
    Fleming, Gini
    Jaskowiak, Nora
    Nanda, Rita
    Olopade, Olufunmilayo I.
    Huo, Dezheng
    CANCER RESEARCH, 2021, 81 (04)